Literature DB >> 7814175

Response of patients with coronary artery disease stratified by ejection fraction following short-term training.

L Szmedra1, D W Bacharach, P J Buckenmeyer, D T Hermann, D A Ehrich.   

Abstract

The purpose of this study was to investigate the response of patients with ischemic heart disease and varied left ventricular function following 6 weeks of exercise training. We studied the oxygen consumption (VO2), and central hemodynamic and metabolic responses of 14 patients with coronary artery disease (CAD) stratified by left ventricular ejection fraction (EF). There were two groups of patients: normal EF (NEF), EF = 64 +/- 9.9 (mean +/- S.E.M.); n = 7, and diminished EF (DEF), EF = 36 +/- 11.6; n = 7. The patients ranged in age from 42 to 72 years (54.9 +/- 2.2), and were evaluated prior to and then following training. Measures of VO2, cardiac output (Qt) stroke volume (SV), heart rate (HR), exercise duration (XTIME) and intensity (XI), as well as plasma lactate (LA), and the catecholamines epinephrine (E) and norepinephrine (NE) were obtained in response to maximal cycle ergometry. Subjects trained three times per week, 30 min per session, at an intensity equal to 70% of their peak oxygen consumption. Repeated measures analysis of variance (ANOVA) revealed no interaction between groups suggesting a similar training response. Significant post-training changes (P < 0.05) were observed in peak VO2 (VO2peak) NEF, 11.8% increase, (16.0 +/- 1.3 to 17.9 +/- 1.1 ml/kg/min) and DEF, 9.3% increase (15.1 +/- 1.6 to 16.5 +/- 1.2 ml/kg/min); submaximal HR, 4% decrease in the NEF (95.57 +/- 4.58 to 92 +/- 4.43 beats/min) and a 6% decrease in the DEF (107.29 +/- 7.44 to 101.43 +/- 6.77 beats/min); XTIME NEF, 11.2% increase (7.8 +/- 0.57 to 8.67 +/- 0.61 min) and DEF, 16.6% increase (7.3 +/- 0.91 to 8.51 +/- 0.69 min); and XI NEF, 19.2% increase (104.3 +/- 11.3 to 124.3 +/- 12.9 W) DEF, 21.2% increase (94.3 +/- 18.5 to 114.3 +/- 16.9 W), and a 15% decrease in resting NE (350 +/- 26 to 296.9 +/- 19 pg/ml). There were no changes in Qt, SV, LA, E, peak NE or peak HR for either group. These findings suggest short-term endurance training at 70% VO2peak provide the necessary stimulus for individuals with CAD and NEF or DEF to display an improvement in XI, XTIME, and VO2peak. The lack of a significant enhancement in Qt with short-term training may indicate that the mechanism by which both study groups were able to attain significantly higher levels of VO2peak may have been attributable to peripheral mechanisms rather than any alterations in Qt, a central mechanism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7814175     DOI: 10.1016/0167-5273(94)90243-7

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  [Transmyocardial laser revascularization and rehabilitation].

Authors:  T Kruse; H Höffken; R Moosdorf; C Bethge; B Maisch
Journal:  Herz       Date:  1997-08       Impact factor: 1.443

2.  Predictors of improvements in exercise capacity during cardiac rehabilitation in the recovery phase after coronary artery bypass graft surgery versus acute myocardial infarction.

Authors:  Yuji Suzuki; Kenichi Ito; Kazuya Yamamoto; Noriyuki Fukui; Hidetoshi Yanagi; Kazufumi Kitagaki; Harumi Konishi; Tetsuo Arakawa; Michio Nakanishi; Yoichi Goto
Journal:  Heart Vessels       Date:  2017-11-08       Impact factor: 2.037

3.  Severe loss of mechanical efficiency in COVID-19 patients.

Authors:  Eulogio Pleguezuelos; Amin Del Carmen; Gemma Llorensi; Jessica Carcole; Paula Casarramona; Eva Moreno; Pilar Ortega; Mateo Serra-Prat; Elisabet Palomera; Marc M Miravitlles; Joan Carles Yebenes; Ramón Boixeda; Lluis Campins; Koldo Villelabeitia-Jaureguizar; Manuel Vicente Garnacho-Castaño
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-06-08       Impact factor: 12.063

Review 4.  Rehabilitation in cardiac patients:what do we know about training modalities?

Authors:  Dominique Hansen; Paul Dendale; Jan Berger; Romain Meeusen
Journal:  Sports Med       Date:  2005       Impact factor: 11.928

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.